Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

19%

4 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (5)
P 1 (2)
P 2 (1)
P 3 (1)
P 4 (3)

Trial Status

Recruiting8
Completed5
Not Yet Recruiting4
Active Not Recruiting3
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT06160128Recruiting

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

NCT07321314RecruitingPrimary

RSV Burden in Hong Kong

NCT07756528Active Not RecruitingPrimary

Stakeholder-Informed RSV Prevention Economic Model in Botswana

NCT07030075Recruiting

Surveillance, Assessment and Detection of Influenza Associated Respiratory Infections in HIV Positive and Negative Individual in Lusaka, Zambia.

NCT07482657Phase 2Recruiting

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

NCT07713628Not ApplicableNot Yet RecruitingPrimary

Immune Reponses to RSV B Challenge in Older Adults (A Controlled Human Infection Study With RSV in Older People-02)

NCT07700134Active Not Recruiting

The Role of Vitamin D and Vitamin D Receptor in Recurrent Wheezing in Children With Bronchiolitis: Immunological Association With T-lymphocyte Mitochondrial Mass

NCT07097012Phase 4RecruitingPrimary

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy

NCT06684743Phase 4Active Not RecruitingPrimary

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

NCT07508644Phase 4Not Yet Recruiting

RSV Vaccination to Reduce Recurrent AECOPD

NCT06689423Completed

Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

NCT07418229Phase 1Not Yet RecruitingPrimary

Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

NCT07308158Completed

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07147517Recruiting

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07217639Not ApplicableNot Yet Recruiting

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT06672692Not ApplicableRecruiting

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

NCT06511687RecruitingPrimary

Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

NCT05585632Phase 1Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05096208Phase 3CompletedPrimary

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05778240Not ApplicableCompleted

Adherence to Palivizumab Prophylaxis

Scroll to load more

Research Network

Activity Timeline